NCT06603597RecruitingNot Applicable
Prospective Evaluation of Outcomes for HER2-positive Breast Cancer (PRO-HER2)
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Priyanka Sharma
- Enrollment
- 1,000
- Locations
- 12
- Primary Endpoint
- Overall survival rate
Study Overview
Brief Summary
The goal of this observational study is to better understand links between patient or tumor characteristics and outcomes in HER2-positive breast cancer.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Stage I-IV HER2-positive breast cancer
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Overall survival rate
Time Frame: From diagnosis to 5 years after diagnosis
For patients with stage I-III HER2-positive breast cancer, percentage of patients who are alive at 5 years after diagnosis.
Secondary Outcomes
- Pathologic complete response rate(From start of neoadjuvant systemic treatment until approximately 8 months after start of neoadjuvant systemic treatment)
Investigators
Priyanka Sharma
Professor of Medicine
University of Kansas Medical Center
Study Sites (12)
Loading locations...
Similar Trials
Completed
Not Applicable
An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 YearsBreast CancerNCT01480674Hoffmann-La Roche160
Completed
Not Applicable
HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin TherapyBreast CancerNCT01777958Hoffmann-La Roche135
Completed
Not Applicable
HER2 and LA/mUC: A Multi-country Chart Review Cohort StudyUrothelial CarcinomaNCT05902494Seagen, a wholly owned subsidiary of Pfizer389
Completed
Not Applicable
A Study of Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a TaxaneMetastasesBreast CancerNCT00097487Genentech, Inc.1,000
Unknown
Phase 2
A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 AloneHER2-positive Breast CancerBrain MetastasesNCT04158947xuexin he130